Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer. Urologic oncology Krajewski, W., Aumatell, J., Subiela, J. D., Nowak, L., Tukiendorf, A., Moschini, M., Basile, G., Poletajew, S., Malkiewicz, B., Giudice, F. D., Maggi, M., Chung, B. I., Cimadamore, A., Galosi, A. B., Fave, R. F., D'Andrea, D., Shariat, S. F., Hornak, J., Babjuk, M., Chorbinska, J., Teoh, J. Y., Muilwijk, T., Joniau, S., Tafuri, A., Antonelli, A., Panunzio, A., Alvarez-Maestro, M., Simone, G., Mastroianni, R., Laszkiewicz, J., Lonati, C., Zamboni, S., Simeone, C., Niedziela, L., Candela, L., Macek, P., Contieri, R., Hidalgo, B. G., Rivas, J. G., Sosnowski, R., Mori, K., Mir, C., Soria, F., Gonzalez-Padilla, D. A., Faba, O. R., Palou, J., Ploussard, G., Rajwa, P., Halon, A., Laukhtina, E., Pradere, B., Tully, K., Burgos, F. J., Cidre, M. A., Szydelko, T., European Association of Urology- Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group 2022

Abstract

PURPOSE: Non-muscle-invasive bladder cancers (NMIBC) constitute 3-quarters of all primary diagnosed bladder tumors. For risk-adapted management of patients with NMIBC, different risk group systems and predictive models have been developed. This study aimed to externally validate EORTC2016, CUETO and novel EAU2021 risk scoring models in a multi-institutional retrospective cohort of patients with high-grade NMIBC who were treated with an adequate BCG immunotherapy.METHODS: The Kaplan-Meier estimates for recurrence-free survival and progression-free survival were performed, predictive abilities were assessed using the concordance index (C-index) and area under the curve (AUC).RESULTS: A total of 1690 patients were included and the median follow-up was 51 months. For the overall cohort, the estimates recurrence-free survival and progression-free survival rates at 5-years were 57.1% and 82.3%, respectively. The CUETO scoring model had poor discrimination for disease recurrence (C-index/AUC for G2 and G3 grade tumors: 0.570/0.493 and 0.559/0.492) and both CUETO (C-index/AUC for G2 and G3 grade tumors: 0.634/0.521 and 0.622/0.525) EAU2021 (c-index/AUC: 0.644/0.522) had poor discrimination for disease progression.CONCLUSION: Both the CUETO and EAU2021 scoring systems were able to successfully stratify risks in our population, but presented poor discriminative value in predicting clinical events. Due to the lack of data, model validation was not possible for EORTC2016. The CUETO and EAU2021 systems overestimated the risk, especially in highest-risk patients. The risk of progression according to EORTC2016 was slightly lower when compared with our population analysis.

View details for DOI 10.1016/j.urolonc.2022.06.008

View details for PubMedID 35851185